Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö > ¹ÙÀÌ¿ÀÀåºñ > Assessment of the Molecular Diagnostic Market for 44 NA Tests in UK
Ä«Å×°í¸®
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö (1590)
°Ô³ð â¾à (202)
¸ÂÃãÇüÀÇ·á (51)
¹ÙÀÌ¿À¸¶Ä¿ (154)
¹ÙÀÌ¿À¸ÅÆ®¸®¾ó (54)
¹ÙÀÌ¿ÀÀåºñ (357)
ºÐÀÚÇ¥ÀûÄ¡·á(MTT) (131)
À¯ÀüÀÚ Ä¡·á/RNAi (101)
Àç»ýÀÇÇÐ (124)
Ç×ü/¸é¿ª (191)
½ÃÀ庸°í¼­

Assessment of the Molecular Diagnostic Market for 44 NA Tests in UK

¸®¼­Ä¡»ç data information intelligence GmbH
¹ßÇàÀÏ 2009³â 09¿ù »óǰÄÚµå 102237
ÆäÀÌÁö Á¤º¸ 65 pages
°¡°Ý
US $ 6,000 £Ü 7,149,000 PDF by E-mail (Single User License)


¿µ¹®¸ñÂ÷

Abstract

This is the most comprehensive European market report on the emergent field of molecular diagnostics from the end user perspective. Hospital and private laboratories have been surveyed to collect information on NA tests performed, test volumes and used platforms and reagents. For data reliability and accurate projections at segment level a 3 step methodology has been applied:

  • Step 1: Identification of the total number of laboratories by secondary research and short telephone interviews with 561 hospitals to verify existence of internal laboratories.
  • Step 2: 355 laboratories in UK were classified for NAT activity and overall NA test volume.
  • Step 3: 36 laboratories provided data on NA test volume, kits, platforms and trends. A list of 44 NA tests have been provided to the labs for structured data entry. All data has been analysed and projected at total market level. The report discusses tests and technologies that are currently available and wishes from the end user perspectives. The report covers key platforms of molecular diagnostics, including Polymerase Chain Reaction (PCR), Real Time PCR (RT-PCR), TMA, LCR, NASBA, SDA, HCA, bDNA.

Table of Contents

  • Total number of clinical diagnostic labs by lab type: small, medium and large hospitals, non hospital (private) labs
  • Number of clinical diagnostic NA labs by lab type: small, medium and large hospitals, non hospital (private) labs, and by NA test volume: >/< 20 NA tests per day
  • # of lab performing test by test types (Adenovirus, BK, C. Diff, CF, CMV, CMV Viral, CT, CT/NG, EBV, EBV Viral, Enterovirus, Factor II, Factor V Leiden, Fragile X, GAS, GBS, HBV qual, HBV resistance, HBV Viral Load, HCV Genotyping, HCV qual, HCV Viral Load, Her2Neu, HIV Genotyping, HIV qual, HIV Viral Load, HLA Typing, HPV, HPV Genotyping, HSV 1, HSV 2, Human Metapneumovirus, Influenza A, B, MAC (formerly MAI), MRSA, MSSA, MTB, MTD (Tuberculosis), NG, Parainfluenza 1,2,3, RSV, Staphylococcus aureus, VRE, VZV, Warfarin sensitivity (CYP2C9, VKOR1))
  • Total # of test/results per test type & growth rate (Adenovirus, BK, C. Diff, CF, CMV, CMV Viral, CT, CT/NG, EBV, EBV Viral, Enterovirus, Factor II, Factor V Leiden, Fragile X, GAS, GBS, HBV qual, HBV resistance, HBV Viral Load, HCV Genotyping, HCV qual, HCV Viral Load, Her2Neu, HIV Genotyping, HIV qual, HIV Viral Load, HLA Typing, HPV, HPV Genotyping, HSV 1, HSV 2, Human Metapneumovirus, Influenza A, B, MAC (formerly MAI), MRSA, MSSA, MTB, MTD (Tuberculosis), NG, Parainfluenza 1,2,3, RSV, Staphylococcus aureus, VRE, VZV, Warfarin sensitivity (CYP2C9, VKOR1))
  • Market share: # of tests/results by supplier (Roche Diagnostics, Innogenetics, Abbott, Bio-Rad, bioMerieux, Stratagene, Applied Biosystems, Qiagen, Siemens, Cepheid, Digene)
  • Installed base of analyzers
  • Trends
Back to Top